Bilateral vision loss secondary to pachymeningitis in a patient with IgG4-related disease

Lucas Ramirez *, Andrea D’Auria, Adeel Popalzai and Nerses Sanossian

Roxanna Todd Hodges Comprehensive Stroke Clinic, University of Southern California, Los Angeles, CA, USA

IgG4-related disease (IgG4-RD) is a recently recognized fibroinflammatory condition associated with disease in nearly every organ, including the meninges. A proportion of idiopathic hypertrophic pachymeningitis cases may involve a component of meningeal IgG4-RD. We present a patient with severe bilateral vision loss found to have thickening of the dura mater on MRI, and subsequently diagnosed with IgG4-RD after dural biopsy.

Keywords: IgG4-related disease, pachymeningitis, vision loss, IgG4, dural thickening

CASE

A 44-year-old man presented to the emergency department with progressive vision loss. He reported worsening vision for 8 days to near blindness, new-onset severe, and pressure like, non-pulsatile headache. Past medical history was remarkable for diabetes, hypertension, dyslipidemia, and rheumatoid arthritis. Vital signs were stable and the neurological examination showed no light perception on the OS, and only hand motion perception on the OD.

Non-contrast CT of the head showed no intracranial abnormality. Ophthalmological evaluation found no apparent explanation for the visual loss. Dexamethasone therapy was initiated. Contrast-enhanced MRI of the brain done 1 day later showed diffuse thickening and enhancement of the dura, greater on the left side (Figure 1A). MRI of the orbits showed bilateral enhancement of the posterior aspect of the intraconal optic nerve sheath (Figure 1B). Lumbar puncture demonstrated an opening pressure of 32 mm H₂O, glucose 90 mg/dL, protein content of 44 mg/dL, RBC 1, and WBC 21 (80% lymphocytes, 16% monocytes, 4% neutrophils). Gram stain, cultures, and cytology were negative. IgG index was 1.09 (reference <0.66), and IgG was 13.3 mg/dL (range 0.8–7.7). A left frontal dural biopsy was performed.

The patient’s vision continued to improve with steroid therapy and on day 10, VA was noted to be 20/20 on the OD and 20/30 on OS. Pathological evaluation showed pachymeningitis with increased IgG4 plasma cells (Figure 2). Given the clinical, laboratory, and pathology results, a diagnosis of IgG4-related disease (IgG4-RD) was made. Serum IgG4 drawn on the day of hospital discharge revealed elevated levels of 182.0 (reference range 4–86).

DISCUSSION

IgG4-related disease is a recently recognized fibroinflammatory condition first linked to autoimmune pancreatitis (AIP) in 2001 when pancreatic specimens from patients with AIP were found to have large numbers of IgG4 positive cells (1). In 2003, Kamisawa et al. reported extrapancreatic lesions in patients with AIP containing histopathology identical to that found in the pancreas. It was thus suggested that AIP was part of a larger systemic disease and not just confined to the pancreas (2).

Since then, IgG4-RD has been associated with disease involving nearly every organ system including pancreas, salivary glands, lacrimal glands, thyroid, pituitary, lungs, aorta, pericardium, liver, biliary tree, kidneys, retroperitoneum, breast, prostate, lymph nodes, skin, periorbital tissues, and the meninges (1–3). Tissues from involved organs demonstrate similar histopathological features of lymphoplasmacytic infiltration, many IgG4 positive plasma cells, and fibrosis (1, 2).

The meninges may be involved either intracranially or intraspinally with a predilection for involvement of the pachymeninges rather than the leptomeninges (1). The MRI findings of thickened dura, along with characteristic histology of fibrosis and lymphoplasmacytic infiltrates, fulfill the clinicopathological features of hypertrophic pachymeningitis (HP), a rare fibroinflammatory lesion causing thickening of cranial and/or spinal dura (4). HP may be due to infections such as tuberculosis and syphilis, systemic autoimmune diseases, neoplasms, or may be idiopathic (4). It is believed that a proportion of previously reported cases of idiopathic hypertrophic pachymeningitis (IHP) actually represent IgG-RD. A recent retrospective study analyzed 10 cases of IHP and showed evidence of IgG4-RD histopathology in 5 of the 10 (2, 3).

IgG4-related vision loss is rare. IgG4-RD can present as non-specific constitutional symptoms at the time of diagnosis, or more likely as a sub-acute expanding mass, with disease confined to a single organ for many years (1, 2). A proportion of cases of IHP have demonstrated IgG4-RD. IHP presents with radiculomyelopathy, headaches, cranial nerve palsies, papilledema, and...
unilateral or bilateral visual loss (1, 2, 4, 5). These presentations can also be included as those of IgG4-RD. The visual loss associated with HP has been attributed to inflammatory optic neuropathy. Other potential mechanisms of visual loss include infiltrative and compressive retrobulbar optic neuropathy (6, 7).

CONCLUSION
We describe a patient with visual loss due to pachymeningitis from IgG4-RD. We believe that a proportion of IHP actually represents IgG4-RD and that clinicians should consider testing for this condition with biopsy and IgG4 immunostaining. Establishing a diagnosis of IgG4-RD is important in planning immunosuppressive therapy to prevent future complications.

TEACHING POINTS
Consider IgG4-RD in the differential diagnosis of HP. Definitive diagnosis of IgG4-RD requires biopsy demonstrating characteristic histopathology along with IgG4 immunostaining. Initial outcome is favorable with corticosteroids, though response is often unsustained in the long-term, thus, additional immunosuppressive agents may be required. Patients with single organ involvement of IgG4-RD should be followed and screened for systemic involvement as disease may develop in multiple locations.

REFERENCES
1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med (2012) 366(6):539–51. doi:10.1056/NEJMra1104650
2. Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol (2011) 23(1):57–66. doi:10.1097/BOR.0b013e3283418057
3. Lindstrom KM, Cousar JB, Lopes MB. IgG4-related meningeal disease: clinicopathological features and proposal for diagnostic criteria. Acta Neuropathol (2010) 120(6):765–76. doi:10.1007/s00401-010-0746-2
4. Chan SK, Cheuk W, Chan KT, Chan JK. IgG4-related sclerosing pachymeningitis: a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol (2009) 33(8):1249–52. doi:10.1097/PAS.0b013e3181ab0c4e
5. Lam BL, Barrett DA, Glaser JS, Schatz NJ, Brown IH. Visual loss from idiopathic intracranial pachymeningitis. Neurology (1994) 44(4):694–8. doi:10.1212/01.WNL.44.4.694
6. Chan JW. Acute monocular visual loss in carcinomatous hypertrophic pachymeningitis mimicking giant cell arteritis. J Clin Rheumatol (2006) 12(1):30–1. doi:10.1097/01.rhu.0000004233.12270.18
7. Liewluck T, Schatz NJ, Potter PE, Romaguera RL. Compressive retrobulbar optic neuropathy due to hypertrophic pachymeningitis. Intern Med (2008) 47(19):1761–2. doi:10.2169/internalmedicine.47.1412

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 29 May 2014; accepted: 15 September 2014; published online: 13 October 2014.

Citation: Ramirez L, D’Auria A, Popalzai A and Sanossian N (2014) Bilateral vision loss secondary to pachymeningitis in a patient with IgG4-related disease. Front. Neurol. 5:192. doi: 10.3389/fneur.2014.00192
This article was submitted to Neurology Education, a section of the journal Frontiers in Neurology.
Copyright © 2014 Ramirez, D’Auria, Popalzai and Sanossian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CCL BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.